Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 14/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24169906 | 1.00 | RNASEL (0.72) | RNASEL | |
| SCHEMBL26067696 | 1.00 | RNASEL (0.72) | RNASEL | |
| SCHEMBL31747744 | 1.00 | RNASEL (0.72) | RNASEL | |
| SCHEMBL24162835 | 1.00 | RNASEL (0.72) | RNASEL | |
| SCHEMBL26067687 | 1.00 | RNASEL (0.72) | RNASEL | |
| SCHEMBL27376372 | 0.99 | RNASEL (0.71) | RNASEL | |
| SCHEMBL26067690 | 0.99 | RNASEL (0.71) | RNASEL | |
| SCHEMBL27376578 | 0.99 | RNASEL (0.71) | RNASEL | |
| SCHEMBL24941695 | 0.96 | RNASEL (0.72) | RNASEL | |
| SCHEMBL26067694 | 0.96 | RNASEL (0.72) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023007019-A9 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | CureVac SE (DE) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023007019-A1 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | CureVac SE (DE) | 2023-02-02 | — | — | WO | disclosed |
| US-20220002716-A1 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002716-A1 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | RNGTT, RNMT, CPSF7 | RNASEL 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.